Core Viewpoint - Haijia Medical (06078.HK) announced a general authorization for share repurchase at the upcoming annual general meeting on June 27, 2025, allowing the company to repurchase up to 61.8499 million shares, representing 10% of the total issued shares as of the meeting date [1] Group 1 - The company’s stock closed at HKD 11.63 on December 15, 2025, with an increase of 0.26% and a trading volume of 4.5822 million shares, resulting in a turnover of HKD 53.1235 million [1] - The investment banks predominantly rate the stock as a buy, with one bank issuing a buy rating in the last 90 days [1] - CITIC Securities recently provided a buy rating for Haijia Medical [1] Group 2 - Haijia Medical has a market capitalization of HKD 7.175 billion and ranks 7th in the medical services sector II [1] - Key performance indicators for the company are summarized in the accompanying table [1]
海吉亚医疗(06078.HK))拟回购公司股份